(NEJM) Preferred therapies for mild-to-moderate COVID-19 include a 3-day intravenous course of remdesivir or nirmatrelvir/ritonavir (Paxlovid). The only published randomized trial of nirmatrelvir/ritonavir was conducted prior to widespread vaccination (N Engl J Med 2022; 386:1397. opens in new tab). Thus, clinicians need further information on the effectiveness of this treatment in more-heavily immune populations. Investigators conducted a retrospective cohort study involving 44,551 patients aged ≥50 (of whom 90% had received at least 3 doses of vaccine) eligible to receive nirmatrelvir/ritonavir. The 28% of patients who received nirmatrelvir/ritonavir had more comorbidities and were more likely to be vaccinated. Black and Hispanic patients — but not patients from disadvantaged neighborhoods — were less likely to receive nirmatrelvir/ritonavir. Hospitalization or death within 28 days of diagnosis occurred in 69 treated patients (0.55%) and 310 untreated patients (0.97%). Adjusted risk ratios for hospitalization (0.60) and death (0.29) favored treatment, particularly in those who were unvaccinated or were >20 weeks from their last immunization. No difference in relative benefit was observed between patients older or younger than 65.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.